Back to Search

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation


  • Protocol Number: 202501222
  • Principal Investigator: Sisk, Bryan
  • Cancer Types: Siteman Kids- Pediatrics

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]